Propranolol Adjuvant Treatment of Focal Refractory Epilepsy (PATFRE)
ConditionEpilepsy, Drug Resistant
Trial statusNot yet recruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age18-60
SponsorXuanwu Hospital, Beijing
About this trial
The aim of this study is to evaluate the clinical efficacy of propranolol as an adjunctive treatment for refractory epilepsy. The significance of this research lies in exploring whether propranolol, as an inhibitor of the CAMP-PKA-MEK/ERK pathway, can provide anticonvulsant effects for a wider range of refractory epilepsy patients. The study holds the potential to offer a novel adjunctive anticonvulsant treatment strategy targeting the CAMP-PKA-MEK/ERK pathway, specifically administered for seizure events, and applicable to various forms of refractory epilepsy.
Eligibility criteria
Qualifiers
18-60 years of age.
Meet the 2017 International League Against Epilepsy (ILAE) diagnostic criteria for for focal seizures or focal seizures progressing to bilateral tonic-clonic seizures.
Diagnosed with refractory epilepsy, having used at least two AEDs without effectiveness for 2 years. No drug interaction between current AEDs and propranolol, and a stable dose for at least 12 weeks prior to enrollment.
Seizure duration ≥1 minute, with accompanying sensory impairment.
Disqualifiers
Diagnosed with generalized or hereditary epilepsy with ion channel gene mutations
Psychogenic non-epileptic seizures within 12 months;
Treatable causes of epilepsy (such as metabolic disorders, toxicity, infections, space-occupying lesions, or identified genetic abnormalities)
Patients with only non-motor focal seizures, as classified by the 2017 ILAE.
Trial design
Treatments tested in this trial
- Propranolol
Treatment groups
15 Participants
are divided into 1 treatment groupLocations
Sponsors and collaborators
Xuanwu Hospital, Beijing
Lead sponsor
Peking University
Collaborator
Source ClinicalTrials.gov